| 000 | 01343 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250517130814.0 | ||
| 264 | 0 | _c20180620 | |
| 008 | 201806s 0 0 eng d | ||
| 022 | _a1365-2559 | ||
| 024 | 7 |
_a10.1111/his.13145 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aParham, David M | |
| 245 | 0 | 0 |
_aThe impact of human epidermal growth factor receptor 2 neoadjuvant monoclonal antibody (trastuzumab) therapy in ductal carcinoma in situ of the breast. _h[electronic resource] |
| 260 |
_bHistopathology _c05 2017 |
||
| 300 |
_a1009-1011 p. _bdigital |
||
| 500 | _aPublication Type: Letter | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xtherapeutic use |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aCarcinoma, Intraductal, Noninfiltrating _xdrug therapy |
| 650 | 0 | 4 |
_aChemotherapy, Adjuvant _xmethods |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoadjuvant Therapy _xmethods |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _ximmunology |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aTrastuzumab _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aPinder, Sarah E | |
| 773 | 0 |
_tHistopathology _gvol. 70 _gno. 6 _gp. 1009-1011 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/his.13145 _zAvailable from publisher's website |
| 999 |
_c26688837 _d26688837 |
||